Before surgeons opened a five-millimeter hole in his skull, a 36-year-old Chinese man asked whether the operation could leave him worse off. He had lost all four limbs in a high-voltage accident years earlier. “At worst, you will be the same as you are now,” his surgeon replied, according to China Science Daily. On March 25, the man underwent experimental brain surgery. Five days later, he could move a computer cursor without touching a screen.
A Clinical First, Not Yet a Cure
On June 16, the Chinese Academy of Sciences announced China's first prospective human clinical trial of an invasive brain-computer interface (BCI). Researchers at its Center for Excellence in Brain Science and Intelligence Technology worked with Fudan University's Huashan Hospital in Shanghai. Researchers described China as the second country, after the United States, to reach this clinical-trial milestone—a distinction that placed one patient's rehabilitation within a growing international technological rivalry.
Selected from more than 200 volunteers, the participant received a coin-sized implant measuring 26 millimeters across and less than six millimeters thick. Two ultraflexible electrodes entered his motor cortex, a brain region involved in movement. The system captures patterns of neural activity and translates intended movement into commands within milliseconds. It does not freely read the contents of his mind.
After two to three weeks of training, he was playing chess and Mario Kart using brain signals. The team reported no infection or electrode failure nearly three months after implantation. But computer games demonstrate control, not restoration of limb function. The scientists next hope to connect the interface to a robotic arm so the patient can grasp a cup; commercial approval, they said, might come in 2028.
The participant told China Science Daily he hoped eventually to control a robotic arm and other intelligent devices. That hope explains why volunteering for an experimental implant can be rational, even amid uncertainty. The surgical team said it had completed 25 practice procedures and secured ethics approval before the operation. Yet short-term stability in one patient cannot establish long-term safety or general effectiveness.
Privacy introduces a second layer of uncertainty. In China Youth Daily, researcher Zhao Zhengtuo said the system shared decoded commands rather than raw brain activity with external devices, and argued that its one-way design eliminated cyberattack risk. The published reporting, however, did not explain who retained the neural recordings, for how long, or what independent security testing had been conducted.
China's 2024 BCI ethics guidelines call for written informed consent, protection of neural data and an unconditional right to leave a study. They also recognize that physicians must decide whether an implant should be removed when research ends. The right to withdraw, in other words, does not necessarily make withdrawal medically or practically simple.
The Complicated Right to Unplug
For a generation raised across the transition from pre-AI devices to algorithmic assistants, software updates and changing privacy policies have become ordinary tradeoffs. Brain implants transform familiar decisions into bodily ones. An upgrade can require surgery. Leaving a platform can mean relinquishing a hard-won ability to communicate or act independently. A consent form signed before implantation cannot anticipate every future dependency.
Zhao, one of the trial's researchers born in the 1990s, described a future in which patients could undergo minor procedures and “always use the latest technology,” China Youth Daily reported. The ambition is understandable. But the phrase exposes another question: who commits to providing those updates if the manufacturer disappears, a trial ends, or a patient refuses another operation?
A documented experience in the United States shows the stakes. Noland Arbaugh, 29 when he became Neuralink's first human implant recipient in 2024, initially regained digital independence before some electrode threads retracted and performance declined. In an August 2024 interview with Lex Fridman, he recalled fearing the new capability might vanish: “It had opened up so many doors for me.” Software changes subsequently improved his control. His experience illustrates neither a failure of China's implant nor a reason to reject BCIs; it illustrates what access can come to mean once experienced.
In a 2022 study of 44 neural-device research stakeholders, many patient-participants did not know whether they could continue using or maintaining their implants after trials. The problem precedes this Chinese experiment, but it grows more urgent as competition rewards the first successful surgery rather than the twentieth year of reliable care.
Perhaps the most consequential measure of a brain interface will not be how quickly it obeys a thought, but whether its user retains meaningful choices after the applause ends.
Explore more exclusive insights at nextfin.ai.
